Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
44.05
-2.80 (-5.98%)
May 5, 2025, 4:00 PM EDT - Market closed
Guardant Health Revenue
Guardant Health had revenue of $203.47M in the quarter ending March 31, 2025, with 20.76% growth. This brings the company's revenue in the last twelve months to $774.00M, up 28.20% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$774.00M
Revenue Growth
+28.20%
P/S Ratio
7.02
Revenue / Employee
$382,977
Employees
2,021
Market Cap
5.46B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
GH News
- 4 days ago - Guardant Health: Tailwinds Are Beginning To Impact The Financials - Seeking Alpha
- 5 days ago - Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - Business Wire
- 6 days ago - Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types - Business Wire
- 7 days ago - CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer - Business Wire
- 7 days ago - Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer - Business Wire
- 11 days ago - Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform - Business Wire
- 13 days ago - Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR - Business Wire